Lushang Freda PharmaceuticalLtd Future Growth
Future criteria checks 4/6
Lushang Freda PharmaceuticalLtd is forecast to grow earnings and revenue by 27.4% and 14.1% per annum respectively. EPS is expected to grow by 26.7% per annum. Return on equity is forecast to be 9.1% in 3 years.
Key information
27.4%
Earnings growth rate
26.7%
EPS growth rate
| Real Estate earnings growth | 38.1% |
| Revenue growth rate | 14.1% |
| Future return on equity | 9.1% |
| Analyst coverage | Good |
| Last updated | 08 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 5,475 | 461 | 51 | 772 | 8 |
| 12/31/2025 | 4,852 | 380 | 3 | 574 | 9 |
| 12/31/2024 | 4,221 | 297 | 2,481 | 2,372 | 9 |
| 9/30/2024 | 3,986 | 237 | 57 | 208 | N/A |
| 6/30/2024 | 4,031 | 240 | 242 | 370 | N/A |
| 3/31/2024 | 4,197 | 233 | 213 | 418 | N/A |
| 12/31/2023 | 4,579 | 303 | 263 | 474 | N/A |
| 9/30/2023 | 7,817 | 130 | -127 | 98 | N/A |
| 6/30/2023 | 10,590 | 47 | 84 | 350 | N/A |
| 3/31/2023 | 12,741 | 108 | 1,263 | 1,442 | N/A |
| 12/31/2022 | 12,951 | 45 | 832 | 998 | N/A |
| 9/30/2022 | 14,543 | 13 | 3,070 | 3,273 | N/A |
| 6/30/2022 | 13,131 | 240 | 4,103 | 4,293 | N/A |
| 3/31/2022 | 12,140 | 342 | 5,970 | 6,250 | N/A |
| 12/31/2021 | 12,363 | 362 | 6,567 | 6,848 | N/A |
| 9/30/2021 | 12,929 | 729 | 7,473 | 7,700 | N/A |
| 6/30/2021 | 14,137 | 710 | 7,719 | 7,944 | N/A |
| 3/31/2021 | 13,915 | 662 | 5,543 | 5,712 | N/A |
| 12/31/2020 | 13,615 | 639 | 4,291 | 4,448 | N/A |
| 9/30/2020 | 10,316 | 572 | 4,680 | 4,841 | N/A |
| 6/30/2020 | 9,817 | 482 | 39 | 174 | N/A |
| 3/31/2020 | 10,307 | 364 | -4,831 | -4,759 | N/A |
| 12/31/2019 | 10,289 | 345 | -3,367 | -3,307 | N/A |
| 9/30/2019 | 10,373 | 222 | -5,546 | -5,516 | N/A |
| 6/30/2019 | 10,159 | 195 | -2,295 | -2,262 | N/A |
| 3/31/2019 | 9,261 | 184 | 3,184 | 3,222 | N/A |
| 12/31/2018 | 8,821 | 162 | 2,062 | 2,095 | N/A |
| 9/30/2018 | 10,105 | 166 | 1,120 | 1,207 | N/A |
| 6/30/2018 | 8,694 | 159 | N/A | 1,571 | N/A |
| 3/31/2018 | 8,476 | 129 | N/A | 360 | N/A |
| 12/31/2017 | 8,287 | 128 | N/A | 1,637 | N/A |
| 9/30/2017 | 7,576 | 102 | N/A | 3,215 | N/A |
| 6/30/2017 | 7,909 | 98 | N/A | -1,495 | N/A |
| 3/31/2017 | 7,370 | 94 | N/A | -1,127 | N/A |
| 12/31/2016 | 7,646 | 92 | N/A | -2,468 | N/A |
| 9/30/2016 | 7,151 | 107 | N/A | -4,768 | N/A |
| 6/30/2016 | 5,870 | 101 | N/A | -1,056 | N/A |
| 3/31/2016 | 6,118 | 103 | N/A | -1,723 | N/A |
| 12/31/2015 | 5,864 | 112 | N/A | -1,798 | N/A |
| 9/30/2015 | 5,109 | 166 | N/A | -991 | N/A |
| 6/30/2015 | 6,365 | 205 | N/A | -1,002 | N/A |
| 3/31/2015 | 5,908 | 207 | N/A | -1,042 | N/A |
| 12/31/2014 | 5,682 | 206 | N/A | -2,363 | N/A |
| 9/30/2014 | 6,387 | 287 | N/A | -2,457 | N/A |
| 6/30/2014 | 5,790 | 273 | N/A | -2,511 | N/A |
| 3/31/2014 | 5,477 | 272 | N/A | -2,356 | N/A |
| 12/31/2013 | 5,293 | 263 | N/A | -1,088 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 600223's forecast earnings growth (27.4% per year) is above the savings rate (2.8%).
Earnings vs Market: 600223's earnings (27.4% per year) are forecast to grow faster than the CN market (26.1% per year).
High Growth Earnings: 600223's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 600223's revenue (14.1% per year) is forecast to grow faster than the CN market (13.8% per year).
High Growth Revenue: 600223's revenue (14.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 600223's Return on Equity is forecast to be low in 3 years time (9.1%).